18889881171
Kalkine 0
countryflagUS

Allogene Therapeutics Inc

Healthcare US ALLO

1.095USD
-0.015(1.35%)

Last update at 2025-05-22T16:59:00Z

Day Range

1.071.11
LowHigh

52 Week Range

1.995.78
LowHigh

Fundamentals

  • Previous Close 1.11
  • Market Cap459.18M
  • Volume470028
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-254.97299M
  • Revenue TTM0.04M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.24M
  • Diluted EPS TTM-1.55

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -332.63200M -257.00500M -250.22100M -184.92500M -211.62200M
Minority interest - - - - -
Net income -329.81500M -244.83700M -233.47100M -184.59400M -211.50500M
Selling general administrative 79.31M 74.11M 65.26M 57.47M 40.98M
Selling and marketing expenses - - - - -
Gross profit 0.24M 38.49M - - 0.00000M
Reconciled depreciation 14.29M 10.45M 7.59M 5.03M 1.50M
Ebit -349.74400M -266.24600M -265.82900M -202.00800M -209.76400M
Ebitda -335.44900M -255.79200M -258.24300M -184.92500M -208.26400M
Depreciation and amortization 14.29M 10.45M 7.59M 17.08M 1.50M
Non operating income net other - -1.21300M 8.02M 17.08M -15.42200M
Operating income -335.44900M -255.79200M -258.24300M -202.00800M -192.84200M
Other operating expenses 335.69M 294.28M 258.24M 202.01M 192.84M
Interest expense -17.11200M 10.45M 9.16M 5.03M 3.36M
Tax provision - 0.00000M 0.00000M -0.33100M -0.11700M
Interest income 4.57M 1.71M 9.16M 17.35M 5.79M
Net interest income 4.57M 1.71M 9.16M 17.35M 2.43M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -2.81700M -12.16800M -16.75000M -0.33100M -0.11700M
Total revenue 0.24M 38.49M 0.00000M 0.00000M 0.00000M
Total operating expenses 335.69M 294.28M 258.24M 202.01M 192.84M
Cost of revenue - - - - 0.00000M
Total other income expense net 2.82M -1.21300M 8.02M 17.08M -21.21100M
Discontinued operations - - - - -
Net income from continuing ops -332.63200M -257.00500M -250.22100M -184.59400M -211.50500M
Net income applicable to common shares -332.63200M -257.00500M -250.22100M -184.59400M -211.50500M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 642.84M 817.08M 1038.63M 1227.83M 717.80M
Intangible assets - - - - 0.15M
Earning assets - - - - -
Other current assets 10.42M 11.50M 14.02M 17.22M 14.04M
Total liab 130.60M 151.21M 122.23M 148.21M 88.78M
Total stockholder equity 512.23M 665.87M 916.41M 1079.62M 629.02M
Deferred long term liab - - - - -
Other current liab 24.32M 33.74M 37.50M 41.96M 23.83M
Common stock 0.17M 0.14M 0.14M 0.14M 0.12M
Capital stock 0.17M 0.14M 0.14M 0.14M 0.12M
Retained earnings -1562.23300M -1235.98000M -903.34800M -646.34300M -396.12200M
Other liab - 1.57M 4.12M 3.08M 4.35M
Good will - - - - -
Other assets - 16.86M 16.11M 263.86M 8.92M
Cash 83.16M 576.47M 809.48M 1032.12M 588.86M
Cash and equivalents - - - - -
Total current liabilities 37.08M 54.52M 48.17M 94.32M 33.08M
Current deferred revenue 0.09M 0.89M 0.42M 38.99M -
Net debt 11.97M -481.34900M -739.55200M -978.33500M -537.50600M
Short term debt 6.78M 6.00M - 2.97M -
Short long term debt - - - - -
Short long term debt total 95.12M 95.12M 69.93M 53.78M 51.35M
Other stockholder equity 2075.25M 1911.63M 1822.18M 1725.55M 1023.88M
Property plant equipment - 196.43M 122.99M 118.84M 100.94M
Total current assets 459.12M 528.82M 809.48M 845.13M 544.58M
Long term investments 3.65M 71.97M 352.18M 204.21M 63.21M
Net tangible assets - 665.87M 916.41M 1079.62M 628.87M
Short term investments 365.54M 455.42M 283.99M 644.56M 355.41M
Net receivables - 3.30M 5.82M 5.17M 2.40M
Long term debt - - - - -
Inventory - - - - -60.72500M
Accounts payable 5.90M 13.89M 10.26M 10.39M 9.25M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.95500M -9.92600M -2.56700M 0.27M 1.15M
Additional paid in capital - - - - -
Common stock total equity - - 0.14M 0.14M 0.12M
Preferred stock total equity - - - - -
Retained earnings total equity - - -903.34800M -646.34300M -396.12200M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 16.90M 32.67M -322.05100M 14.62M 8.92M
Deferred long term asset charges - - - - -
Non current assets total 183.72M 288.25M 229.15M 382.70M 173.23M
Capital lease obligations 95.12M 101.12M 69.93M 53.78M 51.35M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 106.16M 185.10M -439.16500M 214.88M -627.46600M
Change to liabilities 5.33M 3.93M 18.07M 2.94M 20.94M
Total cashflows from investing activities 106.16M 163.66M -505.12300M 164.08M -632.79800M
Net borrowings - - - - 116.84M
Total cash from financing activities 2.95M 11.96M 633.59M 58.96M 771.18M
Change to operating activities -1.62400M 7.25M 14.31M -5.89300M 3.30M
Net income -332.63200M -257.00500M -250.22100M -184.59400M -211.50500M
Change in cash -111.41000M -9.19400M 13.38M 85.69M 93.73M
Begin period cash flow 183.61M 192.80M 179.43M 93.73M 0.00000M
End period cash flow 72.20M 183.61M 192.80M 179.43M 93.73M
Total cash from operating activities -220.51900M -184.81200M -115.09300M -137.35000M -44.65300M
Issuance of capital stock 0.00000M 0.00000M 621.93M 54.22M 642.97M
Depreciation 14.29M 10.45M 7.59M 5.03M 1.50M
Other cashflows from investing activities - - - 214.88M -2.09800M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock 2.46M 3.62M 2.84M 1.78M 654.34M
Other cashflows from financing activities 106.16M 8.35M 8.81M 2.96M 427.49M
Change to netincome 94.11M 80.82M 69.22M 52.51M 129.72M
Capital expenditures 5.19M 21.45M 65.96M 50.79M 3.23M
Change receivables - - - - -
Cash flows other operating - -29.96100M 37.00M -9.63700M 12.37M
Exchange rate changes - - - - -
Cash and cash equivalents changes - -9.19400M 13.38M 85.69M 93.73M
Change in working capital 3.71M -32.08900M 53.92M -6.87800M 12.10M
Stock based compensation 83.60M 80.82M 65.26M 46.06M 18.57M
Other non cash items 2.43M 2.61M 3.96M 3.36M 134.81M
Free cash flow -225.71000M -206.25800M -181.05100M -188.14100M -47.88700M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ALLO
Allogene Therapeutics Inc		 -0.015 1.35% 1.09 - - 10678.65 1.03 6268.06 -1.0393
NVO
Novo Nordisk A/S		 -0.155 0.23% 68.05 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 0.95 1.40% 68.95 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -4.41 1.01% 430.91 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -10.3 1.70% 594.32 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Allogene Therapeutics Inc

210 East Grand Avenue, South San Francisco, CA, United States, 94080

Key Executives

Name Title Year Born
Dr. Arie S. Belldegrun F.A.C.S., FACS, M.D. Co-Founder & Exec. Chairman 1949
Dr. David D. Chang M.D., Ph.D. Co-Founder, Pres, CEO & Director 1960
Mr. Joshua A. Kazam Co-Founder & Director 1977
Dr. Eric Thomas Schmidt Ph.D. Chief Financial Officer 1970
Dr. Alison Moore Ph.D. Chief Technical Officer 1967
Mr. Veer Bhavnagri Gen. Counsel & Compliance Officer 1983
Dr. Rafael G. Amado M.D. Exec. VP of R&D 1964
Ms. Barbra Sasu Chief Scientific Officer NA
Mr. Stephen Cheng Chief Information Officer NA
Ms. Christine Cassiano Chief Communications Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.